Most Read Articles
Jairia Dela Cruz, 12 Apr 2017
Women with multiple gestational diabetes mellitus (GDM) pregnancies may be at an increased risk of developing breast cancer, according to the Sister Study, suggesting the need for increased breast cancer surveillance in this population.
Pearl Toh, 18 Apr 2017
A novel treatment targeting the neurokinin 3 receptor (NK3R) pathway with MLE4901, a NK3R antagonist, significantly reduces the frequency and severity of menopausal hot flushes, as well as the impact on daily life of menopausal women compared with placebo, according to a study presented at The Endocrine Society Annual Meeting (ENDO 2017) in Orlando, Florida, US.
Elvira Manzano, 05 Apr 2017
Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.
17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.

Surgery, medical programme improve physical behaviour, fitness in T2D patients

22 Dec 2016

In patients with type 2 diabetes (T2D), both Roux-en-Y gastric bypass and the medical programme result in therapeutic lifestyle changes and improved objective and self-reported physical fitness, according to a recent study.

Heart rate, oxygen saturation and perceived impact of weight on health had also improved after surgery, and this could have been caused by greater weight loss.

Researchers assessed the physical behaviour and fitness in participants of the Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D) study, with the purpose of comparing the effects of Roux-en-Y gastric bypass with a multidisciplinary, group-based medical diabetes and weight management programme.

SLIMM-T2D is a randomized, parallel-group trial conducted at a US academic hospital and diabetes clinic with 18- to 24-month follow-up. A total of 38 T2D patients with haemoglobin A1c ≥6.5 percent and body mass index (BMI) 30 to 42 kg/m2 were randomly assigned to either Roux-en-Y gastric bypass or the medical programme.

Researchers conducted a 6-minute walk test to evaluate fitness, self-reported physical activity, standardized physical surveys and cardiometabolic risk assessment at baseline and after intervention.

Improvement in the 6-minute walk test distance was seen in both groups, with greater improvements in oxygen saturation and reduced heart rate after surgery.

At 18 to 24 months after interventions, self-reported physical activity similarly improved, while exercise increased gradually after surgery. However, early substantial increases in the medical group were not fully sustained.

After surgery, self-reported total and physical health were similar by Short Form-36 but improved more in the Impact of Weight on Quality of Life survey. Furthermore, greater improvement was found in cardiovascular risk scores, HbA1c and BMI after surgery.

Further research is warranted to better understand the clinical importance of these improvement with greater weight loss, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 12 Apr 2017
Women with multiple gestational diabetes mellitus (GDM) pregnancies may be at an increased risk of developing breast cancer, according to the Sister Study, suggesting the need for increased breast cancer surveillance in this population.
Pearl Toh, 18 Apr 2017
A novel treatment targeting the neurokinin 3 receptor (NK3R) pathway with MLE4901, a NK3R antagonist, significantly reduces the frequency and severity of menopausal hot flushes, as well as the impact on daily life of menopausal women compared with placebo, according to a study presented at The Endocrine Society Annual Meeting (ENDO 2017) in Orlando, Florida, US.
Elvira Manzano, 05 Apr 2017
Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.
17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.